Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Clinicaltrials.gov ID: NCT06171139
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age ≥ 18 Years
b-bullseye-arrow Enrollments 80

Conditions

Prostate Cancer, Prostate Cancer Metastatic

Summary

The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.

Detailed Description

PRIMARY OBJECTIVES:

Stage 1: To evaluate education quality of the intervention in Black or African American men with prostate cancer.

Stage 2: To evaluate feasibility of the TGT intervention among Black or African American men with prostate cancer

SECONDARY OBJECTIVES:

Stage 1:

1. To evaluate completeness of the intervention content.
2. To identify barriers and facilitators for using the intervention.

Stage 2:

1. To evaluate the acceptability of the intervention among Black or African American men with prostate cancer.
2. To evaluate change in participant knowledge about tumor genetic testing among Black or African American men with prostate cancer.
3. To evaluate change in patient attitudes toward tumor genetic testing among Black or African American men with prostate cancer.
4. To evaluate change in participant expectations of tumor genetic testing among Black or African American men with prostate cancer.
5. To evaluate patient perspectives on the intervention.
6. To evaluate the rate of TGT among Black or African American men with prostate cancer who have received the tumor genetic pre-test counseling tool.

OUTLINE:

This is a two-stage study. In Stage 1, Adult Black or African American men with metastatic prostate cancer who have not made a decision about TGT, or who have decided to undergo TGT, or patients who have decline TGT about tumor genetic testing will participate in development by answering questionnaires and utilizing the pilot application for up to 60 days. The investigators will then refine the tool to be piloted in Stage 2.

Stage 2: A pilot study of participants who are planning to have a discussion about undergoing tumor genetic testing with their oncology provider will be invited to join and utilize the tool, and answer questionnaires about the tool.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Principal Investigator

  • Daniel Kwon, MD

Eligibility Criteria

Inclusion Criteria:

Stage 1:

1. Age 18-years-old or older
2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
4. Able to understand study procedures and to comply with them for the entire length of the study.
5. Able to understand a written information sheet and willing to verbally consent.
6. Fluent in English (reading, writing, and speaking)

Stage 2:

1. Age 18-years-old or older
2. Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
4. Able to understand study procedures and to comply with them for the entire length of the study.
5. Fluent in English (reading, writing, and speaking).
6. Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:

1. Somatic DNA testing of already-collected tissue.
2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
3. Blood-based DNA testing to evaluate for circulating tumor DNA.
7. Able to understand a written informed consent document and willing to sign it.

Exclusion Criteria:

Contraindication to any study-related procedure or assessment in either stage.

Study Plan

Stage 1: Tool Development

EXPERIMENTAL

Participants will participate in a semi-structured qualitative interview either by phone, video conference or in-person. A trained interviewer will interview eligible, consenting participants using a semi-structured interview guide to meet objectives. The interview guide is based on The Patient Education Materials Assessment Tool (PEMAT) and the COM-B (capability (C), opportunity (O), and motivation (M))/Behaviour Change Wheel (BCW) framework and will be used to determine an implementation strategy. The interview will be audio-recorded, transcribed verbatim, and analyzed.

  • OTHER:

    Counseling Tool

    Description:

    Non-therapeutic educational intervention
  • OTHER:

    Questionnaires

    Description:

    Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.

Stage 1: Tool Implementation (Pilot Study)

EXPERIMENTAL

Participants will receive the tumor genetic pre-test counseling tool informed by results and themes identified in Stage 1. Participants will receive the non-therapeutic intervention, a pre-TGT counseling tool, and complete pre- and post-intervention surveys and a attend a brief post-intervention interview.

  • OTHER:

    Counseling Tool

    Description:

    Non-therapeutic educational intervention
  • OTHER:

    Questionnaires

    Description:

    Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.

Timeline

  • Last Updated
    December 14, 2023
  • Start Date
    December 14, 2023
  • Today
    January 22, 2025
  • Completion Date ( Estimated )
    August 31, 2025

Similar Trials

light-list-check RECRUITING light-blue-people 21 - 64 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 65 Years